275 related articles for article (PubMed ID: 16862170)
1. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
2. Molecular cloning, characterization and isolation of novel spliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein, UO-44.
Leong CT; Ng CY; Ong CK; Ng CP; Ma ZS; Nguyen TH; Tay SK; Huynh H
Oncogene; 2004 Jul; 23(33):5707-18. PubMed ID: 15184879
[TBL] [Abstract][Full Text] [Related]
3. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.
Dodier P; Piché A
Gynecol Oncol; 2006 Feb; 100(2):254-63. PubMed ID: 16188300
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
7. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
Lu YM; Zhang SL; Meng LR; Zhao YY
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
[TBL] [Abstract][Full Text] [Related]
8. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer.
Yang G; Thompson JA; Fang B; Liu J
Oncogene; 2003 Aug; 22(36):5694-701. PubMed ID: 12944918
[TBL] [Abstract][Full Text] [Related]
9. [Suppression of insulin-like growth factor-1 receptor by RNA interference inhibits cell growth in vitro and induces chemosensitization of HO8910PM cell to cisplatin].
Gao H; Shi J; Ge SF; DI W
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):45-9. PubMed ID: 18366933
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
11. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
12. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
13. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.
Sun G; Zhou J; Yin A; Ding Y; Zhong M
Int J Oncol; 2008 May; 32(5):1065-71. PubMed ID: 18425333
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo.
Zhang X; Wang X; Song X; Liu C; Shi Y; Wang Y; Afonja O; Ma C; Chen YH; Zhang L
Cancer Sci; 2010 Oct; 101(10):2163-70. PubMed ID: 20735432
[TBL] [Abstract][Full Text] [Related]
15. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of ovarian cancer growth by small interfering RNA targeting X-linked inhibitor of apoptosis gene].
Ma JJ; Chen BL; Xin XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Feb; 42(2):124-8. PubMed ID: 17442189
[TBL] [Abstract][Full Text] [Related]
18. S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
He Z; Gao J; Wang Q; Liu M; Li Y; Li X; Tang H; Zheng J
Oncol Rep; 2008 Aug; 20(2):325-32. PubMed ID: 18636193
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
20. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
